Clinical Confirmation of Pan-Amyloid Reactivity of Radioiodinated Peptide 124I-p5+14 (AT-01) in Patients with Diverse Types of Systemic Amyloidosis Demonstrated by PET/CT Imaging
暂无分享,去创建一个
S. Kennel | J. S. Foster | J. Wall | S. Guthrie | C. Wooliver | R. Lands | A. Stuckey | S. Macy | Emily B. Martin | Dustin Powell | B. Whittle | Craig Wooliver | D. Powell
[1] D. Cheng,et al. 124I-Labeled Immuno-PET Targeting hTREM2 for the Diagnosis of Gastric Carcinoma. , 2023, Molecular pharmaceutics.
[2] A. Dispenzieri,et al. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee , 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[3] J. L. Herraiz,et al. Positron range in combination with point-spread-function correction: an evaluation of different implementations for [124I]-PET imaging , 2022, EJNMMI Physics.
[4] J. Mukherjee,et al. [124I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer’s Disease , 2022, Molecules.
[5] S. Estrada,et al. Cardiac microcalcifications in transthyretin (ATTR) amyloidosis. , 2022, International journal of cardiology.
[6] S. Kennel,et al. First in Human Evaluation and Dosimetry Calculations for Peptide 124I-p5+14—a Novel Radiotracer for the Detection of Systemic Amyloidosis Using PET/CT Imaging , 2021, Molecular Imaging and Biology.
[7] T. Ninomiya,et al. Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution. , 2021, Pathology, research and practice.
[8] G. Merlini,et al. How I Treat AL Amyloidosis. , 2021, Blood.
[9] M. Fontana,et al. Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis. , 2021, Cardiology clinics.
[10] J. B. Castelli,et al. Autopsy findings in a patient with primary systemic AL (kappa light chain) amyloidosis , 2021, Autopsy & case reports.
[11] Xiangxi Meng,et al. Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab , 2021, Clinical nuclear medicine.
[12] E. Nordh,et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study , 2020, Lancet Neurology.
[13] Sanjiv J. Shah,et al. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy , 2020, Circulation. Heart failure.
[14] P. Elliott,et al. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. , 2020, JACC. Heart failure.
[15] D. Dingli,et al. Systemic amyloidosis from A (AA) to T (ATTR): a review , 2020, Journal of internal medicine.
[16] Steve Y. Cho,et al. Evaluation of Musculoskeletal and Pulmonary Bacterial Infections With [124I]FIAU PET/CT , 2020, Molecular imaging.
[17] U. Hegenbart,et al. Prognosis and Staging of AL Amyloidosis , 2020, Acta Haematologica.
[18] M. Kijewski,et al. Quantitative Bone-Avid Tracer SPECT/CT for Cardiac Amyloidosis: A Crucial Step Forward. , 2020, JACC. Cardiovascular imaging.
[19] A. Foli,et al. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis , 2020, Blood Cancer Journal.
[20] R. Falk,et al. How to Image Cardiac Amyloidosis: A Practical Approach. , 2020, JACC. Cardiovascular imaging.
[21] A. Petrie,et al. Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers , 2019, British journal of haematology.
[22] R. Falk,et al. Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body 18F-Florbetapir PET/CT , 2019, The Journal of Nuclear Medicine.
[23] M. Pomper,et al. Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation , 2018, The Journal of Nuclear Medicine.
[24] Sanjiv J. Shah,et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.
[25] S. Solomon,et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.
[26] A. Wechalekar,et al. Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[27] Brian M Zeglis,et al. Thiol-Reactive Bifunctional Chelators for the Creation of Site-Selectively Modified Radioimmunoconjugates with Improved Stability. , 2018, Bioconjugate chemistry.
[28] D. Dingli,et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria , 2018, Leukemia.
[29] S. Kennel,et al. Dual-Energy SPECT and the Development of Peptide p5+14 for Imaging Amyloidosis , 2017, Molecular imaging.
[30] Maurizio Conti,et al. Physics of pure and non-pure positron emitters for PET: a review and a discussion , 2016, EJNMMI Physics.
[31] S. Kennel,et al. Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis , 2016, Scientific Reports.
[32] S. Kennel,et al. The pattern recognition reagents RAGE VC1 and peptide p5 share common binding sites and exhibit specific reactivity with AA amyloid in mice , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[33] S. Kennel,et al. Tc-99m Radiolabeled Peptide p5 + 14 is an Effective Probe for SPECT Imaging of Systemic Amyloidosis , 2016, Molecular Imaging and Biology.
[34] G. Merlini,et al. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium , 2015, Advances in Therapy.
[35] E. Uberbacher,et al. Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis , 2015, Molecules.
[36] C. Zeng,et al. The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients , 2014, Clinical kidney journal.
[37] S. Kennel,et al. Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: A positive role for peptide dehalogenation , 2014, Peptides.
[38] A. Dispenzieri,et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics , 2014, Haematologica.
[39] M. Maurer,et al. Nuclear imaging modalities for cardiac amyloidosis , 2014, Journal of Nuclear Cardiology.
[40] Shuji Mizumoto,et al. Glycosaminoglycans are functional ligands for receptor for advanced glycation end‐products in tumors , 2013, The FEBS journal.
[41] M. Lubberink,et al. In Vivo Visualization of Amyloid Deposits in the Heart with 11C-PIB and PET , 2013, The Journal of Nuclear Medicine.
[42] Steven P. Larson,et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] M. Fändrich,et al. Pattern recognition with a fibril-specific antibody fragment reveals the surface variability of natural amyloid fibrils. , 2011, Journal of molecular biology.
[44] M. Fändrich,et al. Amyloid fibril recognition with the conformational B10 antibody fragment depends on electrostatic interactions. , 2011, Journal of molecular biology.
[45] G. Sobue,et al. Systemic but asymptomatic transthyretin amyloidosis 8 years after domino liver transplantation , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[46] Seulki Lee,et al. Peptide-based probes for targeted molecular imaging. , 2010, Biochemistry.
[47] F. Poon,et al. Preliminary experience of 99mTc‐Aprotinin scintigraphy in amyloidosis , 2007, European journal of haematology.
[48] K. Stubenrauch,et al. Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis. , 2003, The American journal of pathology.
[49] I. Cardoso,et al. Aprotinin binding to amyloid fibrils. , 2000, European journal of biochemistry.
[50] E. Franssen,et al. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[51] M. Pepys,et al. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. , 1990, The New England journal of medicine.